Military Rehabilitation and Compensation (Injuries and Diseases Attributable to Defence Service—Presumptive Liability) Determination 2026

made under subsection 27A(3) of the

Military Rehabilitation and Compensation Act 2004

Compilation No. 1

Compilation date: 26 September 2026

Includes amendments: F2026L01302

Prepared by the Office of Parliamentary Counsel, Canberra

Authorised Version F2026C00964 registered 02/10/2026

About this compilation

This compilation

This is a compilation of the *Military Rehabilitation and Compensation (Injuries and Diseases Attributable to Defence Service—Presumptive Liability) Determination 2026* that shows the text of the law as amended and in force on 26 September 2026 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).

Application, saving and transitional provisions

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Presentational changes

The *Legislation Act 2003* provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1
1 Name 1
3 Authority 1
4 Definitions 1
5 Application 2

Part 2—Injuries and diseases attributable to specified defence service 3
6 Interpretation of this Part 3
7 Attributable injuries and diseases 3

Part 3—Secondary injuries and diseases attributable to any defence service 10
8 Attributable injuries and diseases 10

Part 4—Injuries and diseases attributable to certain defence service involving abuse 13
9 Attributable injuries and diseases 13

Part 5—Diseases attributable to Point Cook firefighting work 16
10 Attributable diseases 16

Part 6—Diseases attributable to F-111 deseal/reseal work 18
11 Attributable diseases 18

Part 7—Cancers attributable to firefighting work 20
12 Meaning of firefighter 20
13 Attributable diseases 20

Part 8—Occupational diseases attributable to specified defence service 23
14 Attributable diseases 23

Part 9—Occupational asthma attributable to specified defence service 31
15 Attributable disease—occupational asthma 31

Endnotes 38

Endnote 1—About the endnotes 38

Endnote 2—Abbreviation key 39

Endnote 3—Legislation history 40

Endnote 4—Amendment history 41

Authorised Version F2026C00964 registered 02/10/2026

Authorised Version F2026C00964 registered 02/10/2026

Part 1—Preliminary

1 Name

This instrument is the *Military Rehabilitation and Compensation (Injuries and Diseases Attributable to Defence Service—Presumptive Liability) Determination 2026*.

3 Authority

(1) This instrument is made under subsection 27A(3) of the *Military Rehabilitation and Compensation Act 2004*.

(2) For the purposes of subsection (1), this instrument is made in reliance upon section 24A of the *Military Rehabilitation and Compensation (Consequential and Transitional Provisions) Act 2004* and section 4 of the *Acts Interpretation Act 1901*.

4 Definitions

Note: A number of expressions used in this instrument are defined in the Act, including the following:
(a) Commission;
(b) defence service;
(c) full-time service;
(d) disease;
(e) injury;
(f) member;
(g) non-warlike service;
(h) peacetime service.

In this instrument:

accepted condition means a service injury or service disease for which the Commission has accepted liability under the Act.

Act means the *Military Rehabilitation and Compensation Act 2004*.

maximum redress or reparation scheme payment means one of the following redress or reparation scheme payments:
(a) a category 4 Defence Abuse Response Taskforce payment; or
(b) a tier 1 Defence Force Ombudsman Reparation Scheme payment; or
(c) a maximum National Redress Scheme for victims of institutional child sexual abuse payment.

onset means:
(a) in relation to an injury—the time when the injury was sustained;

Authorised Version F2026C00964 registered 02/10/2026

(b) in relation to a disease—the time when all the signs and symptoms of the disease were first present as determined by a relevant medical practitioner.

Note: For the purposes of this instrument, the term 'onset' has a different meaning to the term 'onset date' appearing in subsection 5(1) of the Act.

redress or reparation scheme payment means a redress or reparation payment in relation to abuse in the Defence Force from or under any of the following:

(a) the Defence Abuse Response Taskforce; or

(b) the Defence Force Ombudsman Reparation Scheme; or

(c) the National Redress Scheme for victims of institutional child sexual abuse.

warlike service includes:

(a) warlike service as defined in the Act; and

(b) qualifying service as defined in section 7A of the *Veterans' Entitlements Act 1986*.

5 Application

This instrument applies to a claim:

(a) under paragraphs 319(1)(a), (b) or (c) of the Act; and

(b) that is made on or after 1 July 2026.

Authorised Version F2026C00964 registered 02/10/2026

Part 2—Injuries and diseases attributable to specified defence service

6 Interpretation of this Part

For the purposes of this Part, a reference to a kind of defence service, including peacetime service, warlike service and non-warlike service, is a reference to full-time service (whether consecutive or not).

7 Attributable injuries and diseases

An injury or disease specified in column 1 of an item in the table is attributable to the kind of defence service specified in column 2 of the item.

	Column 1	Column 2
Item	**Injury/disease**	**Kind of defence service**
1	Achilles tendinopathy, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item.	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.
2	Acute articular cartilage tear, but only if onset occurs during the defence service specified for this item.	Any defence service.
3	Acute meniscal tear of the knee, but only if onset occurs during the defence service specified for this item.	Any defence service.
4	Adjustment disorder, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 3 months after the last day of defence service specified for this item.	Warlike service: (a) for more than 28 days; and (b) excluding the first 28 days of warlike service.
5	Anxiety disorder, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 5 years after the last day of defence service specified for	Warlike service: (a) for more than 28 days; and (b) excluding the first 28 days of warlike service.

Authorised Version F2026C00964 registered 02/10/2026

Section 7

	this item.	
6	Cataract	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
7	Chondromalacia patella, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.
8	Cut, stab, abrasion or laceration, but only if onset occurs during the defence service specified for this item.	Any defence service.
9	Dislocation of a joint or subluxation of a joint, but only if onset occurs during the defence service specified for this item.	Any defence service.
10	Explosive blast injury, but only if onset occurs during the defence service specified for this item.	Any defence service.
11	Femoroacetabular impingement syndrome, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 5 years after the last day of defence service specified for this item.	Defence service: (a) for more than 5 years; and (b) excluding the first 5 years of defence service in the following roles: (c) special forces, including: (i) Special Air Service Regiment; and (ii) Commandos; and (iii) Special Operations Engineer Regiment; and (iv) Clearance Divers; or (d) Airfield Defence Guards; (e) infantry; or (f) engineers.
12	Fracture, but only if onset occurs during the defence service specified for this item.	Any defence service.
13	Gluteal tendinopathy, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.

Authorised Version F2026C00964 registered 02/10/2026

	this item.	
14	Gunshot injury, but only if onset occurs during the defence service specified for this item.	Any defence service.
15	Heat-induced burn, but only if onset occurs during the defence service specified for this item.	Any defence service.
16	Iliotibial band syndrome (runner's knee), but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item.	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.
17	Internal derangement of the knee, but only if onset occurs: (a) during the defence service specified for this item; or (b) within one year after the last day of defence service specified for this item.	Any defence service.
18	Joint instability, but only if onset occurs during the defence service specified for this item.	Any defence service.
19	Labral tear, but only if onset occurs during the defence service specified for this item.	Any defence service.
20	Medial tibial stress syndrome (shin splints), but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item.	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.
21	Merkel cell carcinoma	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
22	Osteoarthritis (of a joint of a lower limb), but only if onset occurs: (a) during the defence service specified for this item; or (b) within 25 years after the last day of defence service specified for this item.	Peacetime service: (a) for more than 200 days; and (b) excluding the first 200 days of peacetime service.

Authorised Version F2026C00964 registered 02/10/2026

Section 7

23	Osteoarthritis (of a joint of a lower limb)	Warlike or non-warlike service: (a) for more than 133 days; and (b) excluding the first 133 days of warlike or non-warlike service.
24	Otitic barotrauma, but only if onset occurs during the defence service specified for this item.	Defence service: (a) in special forces, including: (i) Special Air Service Regiment; and (ii) Commandos; and (iii) Special Operations Engineer Regiment; or (b) as an engineer with a role involving the disposal/use of explosive ordinance; or (c) as a clearance/ships' diver; or (d) as a submariner; or (e) as a pilot or aircrew; or (f) as aeromedical evacuation personnel; or (g) as underwater medicine medical personnel (officer or medic).
25	Patellar tendinopathy, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item.	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.
26	Pinguecula (conjunctival degeneration)	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
27	Plantar fasciitis, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 2 months after the last day of defence service specified for this item.	Defence service: (a) for more than 60 days; and (b) excluding the first 60 days of defence service.
28	Posttraumatic stress disorder	Warlike service: (a) for more than 28 days; and (b) excluding the first 28 days of warlike service.
29	Primary malignant melanoma of the skin	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
30	Primary malignant neoplasm of the	Defence service being:

Authorised Version F2026C00964 registered 02/10/2026

	eye	(a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
31	Primary non-melanoma malignant neoplasm (NMMN) of the skin	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
32	Pterygium	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
33	Retrocalcaneal heel bursitis, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item.	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.
34	Rotator cuff syndrome, but only if onset occurs: (a) during the defence service specified for this item; or (b) within one month after the last day of defence service specified for this item.	Peacetime service: (a) for more than 210 days; and (b) excluding the first 210 days of peacetime service.
35	Rotator cuff syndrome, but only if onset occurs: (a) during the defence service specified for this item; or (b) within one month after the last day of defence service specified for this item.	Warlike or non-warlike service: (a) for more than 120 days; and (b) excluding the first 120 days of warlike or non-warlike service.
36	Sensorineural hearing loss	Any defence service.
37	Sinus barotrauma, but only if onset occurs during the defence service specified for this item.	Defence service: (a) in special forces, including: (i) Special Air Service Regiment; and (ii) Commandos; and (iii) Special Operations Engineer Regiment; or (b) as an engineer with a role involving the disposal/use of explosive ordinance; or (c) as a clearance/ships' diver; or (d) as a submariner; or (e) as a pilot or aircrew; or

Authorised Version F2026C00964 registered 02/10/2026

Section 7

		(f) as aeromedical evacuation personnel; or (g) as underwater medicine medical personnel (officer or medic).
38	Solar keratosis	Defence service being: (a) peacetime service for at least 56 weeks; or (b) warlike service or non-warlike service for at least 29 weeks.
39	Sprain and strain, but only if onset occurs during the defence service specified for this item.	Any defence service.
40	Thoracolumbar intervertebral disc prolapse, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 5 years after the last day of defence service specified for this item.	Peacetime service: (a) for more than 148 weeks; and (b) excluding the first 148 weeks of peacetime service.
41	Thoracolumbar intervertebral disc prolapse, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 10 years after the last day of defence service specified for this item.	Warlike or non-warlike service: (a) for more than 504 days; and (b) excluding the first 504 days of warlike or non-warlike service.
42	Thoracolumbar spondylosis (also known as thoracic and lumbar spondylosis), but only if onset occurs: (a) during the defence service specified for this item; or (b) within 25 years after the last day of defence service specified for this item.	Peacetime service: (a) for more than 200 days; and (b) excluding the first 200 days of peacetime service.
43	Thoracolumbar spondylosis (also known as thoracic and lumbar spondylosis)	Warlike or non-warlike service: (a) for more than 133 days; and (b) excluding the first 133 days of warlike or non-warlike service.
44	Tinea, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 28 days after the last day of defence service specified for this item.	Any defence service.
45	Tinnitus	Any defence service.
46	Traumatic contusion or haematoma,	Any defence service.

Authorised Version F2026C00964 registered 02/10/2026

	but only if onset occurs during the defence service specified for this item.	
47	Trochanteric bursitis, but only if onset occurs: (a) during the defence service specified for this item; or (b) within 4 weeks after the last day of defence service specified for this item.	Defence service: (a) for more than 28 days; and (b) excluding the first 28 days of defence service.

Authorised Version F2026C00964 registered 02/10/2026

Part 3—Secondary injuries and diseases attributable to any defence service

8 Attributable injuries and diseases

An injury or disease specified in the table is attributable to any defence service.

Item	Injury/disease
1	Alcohol use disorder, but only if at least one of the following is an accepted condition that is present at the time of onset: (a) substance use disorder; (b) depressive disorder.
2	Anosmia, but only if alcohol use disorder is an accepted condition that is present at the time of onset.
3	Aortic aneurysm or aortic wall disorder, but only if hypertension is an accepted condition that is present before onset.
4	Aortic stenosis, but only if at least one of the following is an accepted condition that is present before onset: (a) diabetes mellitus; (b) hypertension.
5	Atrial fibrillation or atrial flutter, but only if hypertension is an accepted condition that is present at the time of onset.
6	Bipolar disorder, but only if substance use disorder is an accepted condition that is present at the time of onset.
7	Bronchiectasis, but only if inflammatory bowel disease is an accepted condition that is present at the time of onset.
8	Cardiomyopathy, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
9	Carotid artery disease, but only if at least one of the following is an accepted condition that is present before onset: (a) diabetes mellitus; (b) hypertension.
10	Cataract, but only if diabetes mellitus is an accepted condition that is present before onset.
11	Cerebrovascular accident, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
12	Chronic pruritus ani, but only if at least one of the following is an accepted condition that is present at the time of onset: (a) diabetes mellitus; (b) inflammatory bowel disease.
13	Conjunctivitis, but only if diabetes mellitus is an accepted condition that is present at the time of onset.

Authorised Version F2026C00964 registered 02/10/2026

14	Depressive disorder, but only if alcohol use disorder is an accepted condition that is present at the time of onset.
15	Dupuytren disease, but only if: (a) diabetes mellitus is an accepted condition that is present before onset; or (b) alcohol use disorder is an accepted condition that is present at the time of onset.
16	Erectile dysfunction, but only if at least one of the following is an accepted condition that is present at the time of onset: (a) depressive disorder; (b) diabetes mellitus; (c) hypertension.
17	Female sexual dysfunction, but only if depressive disorder is an accepted condition that is present at the time of onset.
18	Gingivitis, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
19	Heart block, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
20	IgA nephropathy, but only if inflammatory bowel disease is an accepted condition that is present at the time of onset.
21	Immune thrombocytopaenia, but only if inflammatory bowel disease is an accepted condition that is present at the time of onset.
22	Ischaemic heart disease, but only if at least one of the following is an accepted condition that is present before onset: (a) diabetes mellitus; (b) hypertension.
23	Non-aneurysmal aortic atherosclerotic disease, but only if at least one of the following is an accepted condition that is present before onset: (a) diabetes mellitus; (b) hypertension.
24	Non-Hodgkin lymphoma, but only if inflammatory bowel disease is an accepted condition that is present before onset.
25	Osteomyelitis, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
26	Otitis externa, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
27	Periodontitis, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
28	Peripheral artery disease, but only if at least one of the following is an accepted condition that is present before onset: (a) diabetes mellitus; (b) hypertension.
29	Peripheral neuropathy, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
30	Porphyria cutanea tarda, but only if alcohol use disorder is an accepted condition that is

Authorised Version F2026C00964 registered 02/10/2026

	present at the time of onset.
31	Renal artery atherosclerotic disease, but only if diabetes mellitus is an accepted condition that is present before onset.
32	Renal stone disease, but only if at least one of the following is an accepted condition that is present at the time of onset: (a) diabetes mellitus; (b) inflammatory bowel disease.
33	Retinal vascular occlusion, but only if at least one of the following is an accepted condition that is present before onset: (a) diabetes mellitus; (b) hypertension.
34	Sick sinus syndrome, but only if hypertension is an accepted condition that is present at the time of onset.
35	Steatohepatitis, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
36	Subarachnoid haemorrhage, but only if hypertension is an accepted condition that is present at the time of onset.
37	Subdural haematoma, but only if alcohol use disorder is an accepted condition that is present at the time of onset.
38	Substance use disorder, but only if at least one of the following is an accepted condition that is present at the time of onset: (a) alcohol use disorder; (b) depressive disorder.
39	Suicide or attempted suicide, but only if at least one of the following is an accepted condition that is present at the time of onset: (a) alcohol use disorder; (b) depressive disorder; (c) substance use disorder.
40	Tinea, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
41	Tooth wear (attrition), but only if bruxism is an accepted condition that is present at the time of onset.
42	Tooth wear (tooth erosion), but only if alcohol use disorder is an accepted condition that is present at the time of onset.
43	Trigeminal neuropathy, but only if diabetes mellitus is an accepted condition that is present at the time of onset.
44	Trigger finger, but only if diabetes mellitus is an accepted condition that is present before onset.
45	Tuberculosis, but only if alcohol use disorder is an accepted condition that is present before onset.

Authorised Version F2026C00964 registered 02/10/2026

Part 4—Injuries and diseases attributable to certain defence service involving abuse

9 Attributable injuries and diseases

An injury or disease specified in the table below is attributable to defence service involving abuse in respect of which the person with the injury or disease received a redress or reparation scheme payment.

Item	Injury/disease
1	Adjustment disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 3 months after the last day of defence service involving abuse.
2	Alcohol use disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 6 months after the last day of defence service involving abuse.
3	Anxiety disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 6 months after the last day of defence service involving abuse.
4	Bipolar disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 6 months after the last day of defence service involving abuse.
5	Chronic insomnia disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within one year after the last day of defence service involving abuse.
6	Depressive disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 6 months after the last day of defence service involving abuse.
7	Eating disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 2 years after the last day of defence service involving abuse.
8	Panic disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 2 years after the last day of defence service involving abuse.
9	Substance use disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 6 months after the last day of defence service involving abuse.
10	Suicide and attempted suicide, but only if it occurs: (a) during the defence service involving abuse; or (b) within 10 years after the last day of defence service involving abuse.

Authorised Version F2026C00964 registered 02/10/2026

Section 9

An injury or disease specified in the table below is attributable to warlike or non-warlike service involving abuse in respect of which the person with the injury or disease received a redress or reparation scheme payment.

Item	Injury/disease
1	Bruxism, but only if onset occurs during the warlike or non-warlike service involving abuse.
2	Herpes simplex (orofacial and genital herpes simplex only), but only if onset occurs during the warlike or non-warlike service involving abuse.
3	Inflammatory bowel disease, but only if onset occurs: (a) during the warlike or non-warlike service involving abuse; or (b) within 30 days after the last day of warlike or non-warlike service involving abuse.
4	Irritable bowel syndrome, but only if onset occurs: (a) during the warlike or non-warlike service involving abuse; or (b) within one year after the last day of warlike or non-warlike service involving abuse.
5	Psoriasis, but only if onset occurs: (a) during the warlike or non-warlike service involving abuse; or (b) within 6 months after the last day of warlike or non-warlike service involving abuse.
6	Tension-type headache, but only if onset occurs: (a) during the warlike or non-warlike service involving abuse; or (b) within one year after the last day of warlike or non-warlike service involving abuse.

An injury or disease specified in the table below is attributable to defence service involving abuse in respect of which the person with the injury or disease received a maximum redress or reparation scheme payment.

Item	Injury/disease
1	Acute stress disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 30 days after the last day of defence service involving abuse.
2	Adjustment disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 3 months after the last day of defence service involving abuse.
3	Alcohol use disorder, but only if onset occurs: (a) during the defence service specified for involving abuse; or (b) within 2 years after the last day of defence service involving abuse .
4	Anxiety disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 2 years after the last day of defence service involving abuse.
5	Bipolar disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 6 months after the last day of defence service involving abuse.
6	Depressive disorder, but only if onset occurs:

Authorised Version F2026C00964 registered 02/10/2026

	(a) during the defence service involving abuse; or (b) within 2 years after the last day of defence service involving abuse.
7	Female sexual dysfunction, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 5 years after the last day of defence service involving abuse.
8	Panic disorder, but only if onset occurs: (a) during the defence service specified involving abuse; or (b) within 2 years after the last day of defence service involving abuse.
9	Personality disorder, but only if onset occurs: (a) during the defence service specified involving abuse; or (b) within one year after the last day of defence service involving abuse.
10	Posttraumatic stress disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) after the last day of defence service involving abuse.
11	Schizophrenia, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 3 months after the last day of defence service involving abuse.
12	Substance use disorder, but only if onset occurs: (a) during the defence service involving abuse; or (b) within 2 years after the last day of defence service involving abuse.
13	Suicide and attempted suicide, but only if it occurs: (a) during the defence service involving abuse; or (b) after the last day of defence service involving abuse.

Authorised Version F2026C00964 registered 02/10/2026

Part 5—Diseases attributable to Point Cook firefighting work

10 Attributable diseases

A disease specified in the table is attributable to defence service:

(a) at RAAF Base Point Cook between 1 January 1957 and 31 December 1986; and

(b) involving work relating to any of the following:
  (i) firefighting; or
  (ii) participating in a firefighting training course; or
  (iii) instructing participants in a firefighter training course.

Item	Disease
1	Acquired colour vision deficiency
2	Agoraphobia with panic disorder
3	Anxiety
4	Bipolar disorder
5	Bowel polyps
6	Cauda equina syndrome
7	Depression
8	Diverticular disease
9	Dysplastic naevus
10	Eczema or dermatitis
11	Erectile dysfunction
12	Impaired cognition
13	Irritable bowel disorder
14	Liver disease (excluding diabetes)
15	Memory loss
16	Mixed connective tissue disease
17	Multiple sclerosis
18	Myeloproliferative disorders
19	Neurogenic bladder
20	Non-alcoholic toxic encephalopathy
21	Pancreatic disease
22	Panic disorders
23	Parkinson disease
24	Peripheral neuropathy

Authorised Version F2026C00964 registered 02/10/2026

25	Primary malignant neoplasms
26	Sarcoidosis
27	Sleep disorders with a neurological basis
28	Spinal muscular atrophy
29	Systemic lupus erythematosus
30	Ulcerative colitis/Crohn's disease
31	Vertigo

Authorised Version F2026C00964 registered 02/10/2026

Part 6—Diseases attributable to F-111 deseal/reseal work

11 Attributable diseases

(1) For the purposes of this Part, ***F-111 Tier personnel*** means a person who has been determined to have Tier 1, Tier 2, or Tier 3 status for the purposes of Group 1 participation in the Study of Health Outcomes in Aircraft Maintenance Personnel (SHOAMP) Health Care Scheme administered by the Department.

(2) A disease specified in the table is attributable to defence service as a F-111 Tier personnel.

Item	Disease
1	Acquired colour vision deficiency
2	Agoraphobia with panic disorder
3	Anxiety
4	Bipolar disorder
5	Bowel polyps
6	Cauda equina syndrome
7	Depression
8	Diverticular disease
9	Dysplastic naevus
10	Eczema or dermatitis
11	Erectile dysfunction
12	Impaired cognition
13	Irritable bowel disorder
14	Liver disease (excluding diabetes)
15	Memory loss
16	Mixed connective tissue disease
17	Multiple sclerosis
18	Myeloproliferative disorders
19	Neurogenic bladder
20	Non-alcoholic toxic encephalopathy
21	Pancreatic disease
22	Panic disorders
23	Parkinson disease
24	Peripheral neuropathy
25	Primary malignant neoplasms
26	Sarcoidosis
27	Sleep disorders with a neurological basis

Authorised Version F2026C00964 registered 02/10/2026

28	Spinal muscular atrophy
29	Systemic lupus erythematosus
30	Ulcerative colitis/Crohn’s disease
31	Vertigo

Authorised Version F2026C00964 registered 02/10/2026

Part 7—Cancers attributable to firefighting work

12 Meaning of firefighter

For the purposes of this Part, a member is taken to have rendered defence service as a ***firefighter*** if firefighting or related service made up a substantial portion of the member's service.

13 Attributable diseases

A disease specified in column 1 of an item in the table is attributable to the kind of defence service specified in column 2 of the item.

	Column 1	Column 2
Item	**Disease**	**Kind of defence service**
1	Malignant mesothelioma	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
2	Multiple myeloma	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
3	Primary leukemia	Defence service: (a) as a firefighter for at least 5 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
4	Primary malignant neoplasm of the bladder	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and involving exposure to the hazards of a fire scene during that period.
5	Primary malignant neoplasm of the brain	Defence service: (a) as a firefighter for at least 5 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
6	Primary malignant neoplasm of the breast	Defence service: (a) as a firefighter for at least 10 years (whether consecutive or not); and

Authorised Version F2026C00964 registered 02/10/2026

		(b) involving exposure to the hazards of a fire scene during that period.
7	Primary malignant neoplasm of the cervix	Defence service: (a) as a firefighter for at least 10 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
8	Primary malignant neoplasm of the colon or rectum	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
9	Primary malignant neoplasm of the kidney	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
10	Primary malignant neoplasm of the lung	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
11	Primary malignant neoplasm of the oesophagus	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
12	Primary malignant neoplasm of the ovary	Defence service: (a) as a firefighter for at least 10 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
13	Primary malignant neoplasm of the pancreas	Defence service: (a) as a firefighter for at least 10 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
14	Primary malignant neoplasm of the penis	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
15	Primary malignant neoplasm of the prostate	Defence service:

Authorised Version F2026C00964 registered 02/10/2026

		(a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
16	Primary malignant neoplasm of the skin	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
17	Primary malignant neoplasm of the testis	Defence service: (a) as a firefighter for at least 10 years (whether consecutive or not); and involving exposure to the hazards of a fire scene during that period.
18	Primary malignant neoplasm of the thyroid	Defence service: (a) as a firefighter for at least 10 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
19	Primary malignant neoplasm of the ureter	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.
20	Primary non-Hodgkin lymphoma	Defence service: (a) as a firefighter for at least 15 years (whether consecutive or not); and (b) involving exposure to the hazards of a fire scene during that period.

Authorised Version F2026C00964 registered 02/10/2026

Part 8—Occupational diseases attributable to specified defence service

14 Attributable diseases

A disease specified in column 1 of an item in the table is attributable to the kind of defence service specified in column 2 of the item.

	Column 1	Column 2
Item	**Disease**	**Kind of defence service**
Infectious diseases		
1	Anthrax	Defence service involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts.
2	Brucellosis	Defence service involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts; or (d) animal waste.
3	Hepatitis A	Defence service involving work with human waste.
4	Hepatitis B or Hepatitis C	Defence service involving work with human body fluids.
5	Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)	Defence service involving work with: (a) needles in a healthcare services setting; or (b) sharps in a healthcare services setting.
6	Leptospirosis	Defence service involving work with: (a) animals; or (b) animal carcasses; or (c) animal parts; or (d) animal waste.
7	Orf	Defence service involving work with: (a) goats; or (b) goat carcasses; or (c) sheep; or (d) sheep carcasses.
8	Q-fever	Defence service involving work with: (a) animals; or (b) animal carcasses; or

Authorised Version F2026C00964 registered 02/10/2026

		(c) animal parts.
9	Tuberculosis	Defence service involving work with: (a) animals: (i) in a farming setting; or (ii) in a veterinarian setting; or (b) animal carcasses: (i) in a farming setting; or (ii) in a veterinarian setting; or (c) human corpses: (i) in a healthcare services setting; or (ii) in a mortuary setting; or (d) persons (individuals) in a healthcare services setting.
Malignant diseases		
10	Primary malignant neoplasm of the salivary gland	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
11	Primary malignant neoplasm of the nasopharynx	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) formaldehyde; or (b) wood.
12	Primary malignant neoplasm of the oesophagus	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
13	Primary malignant neoplasm of the stomach	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
14	Primary malignant neoplasm of the colon or rectum	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
15	Primary malignant neoplasm of the liver	Defence service for at least 5 years (whether consecutive or not) involving work with vinyl chloride monomer.
16	Primary malignant neoplasm of the nasal cavity or para-nasal sinuses	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) nickel; or

Authorised Version F2026C00964 registered 02/10/2026

		(d) leather; or (e) wood.
17	Primary malignant neoplasm of the larynx	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material; or (c) acid mist (strong inorganic).
18	Primary malignant neoplasm of the lung caused by asbestos	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material.
19	Primary malignant neoplasm of the bone	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
20	Primary malignant neoplasm of the mesothelium	Defence service for at least one year (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material.
21	Primary malignant neoplasm of the breast	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
22	Primary malignant neoplasm of the ovary	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material.
23	Primary malignant neoplasm of the kidney	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) trichloroethylene.
24	Primary malignant neoplasm of urothelial tissue lining the urinary tract	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) 2-naphthylamine; or (d) benzidine; or (e) cyclophosphamide; or (f) ortho-toluidine; or (g) polycyclic aromatic hydrocarbons during aluminium production.

Authorised Version F2026C00964 registered 02/10/2026

Section 14

25	Primary malignant neoplasm of the brain	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
26	Primary malignant neoplasm of the thyroid	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
27	Primary leukaemia (excluding chronic lymphatic leukaemia)	Defence service for at least 2 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation; or (c) benzene; or (d) butadiene; or (e) cyclophosphamide; or (f) formaldehyde.
28	Primary non-Hodgkin lymphoma	Defence service for at least 2 years (whether consecutive or not) involving work with: (a) equipment that produces ionising radiation; or (b) substances that emit ionising radiation.
Diseases of the nervous system		
29	Parkinson disease	Defence service for at least one year (whether consecutive or not) involving work with manganese.
30	Peripheral neuropathy	Defence service for at least one year (whether consecutive or not) involving work with: (a) acrylamide; or (b) arsenic; or (c) carbon disulphide; or (d) lead; or (e) mercury; or (f) n-hexane; or (g) organophosphates; or (h) trichloroethylene.
Respiratory diseases		
31	Coal workers' pneumoconiosis	Defence service for at least 5 years (whether consecutive or not) involving work with coal.
32	Asbestosis	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) asbestos; or (b) asbestos-containing material.
33	Silicosis	Defence service for at least 5 years (whether

Authorised Version F2026C00964 registered 02/10/2026

		consecutive or not) involving work with: (a) material containing crystalline silica; or (b) silica.
34	Other pneumoconiosis	Defence service for at least 5 years (whether consecutive or not) involving work with: (a) aluminium; or (b) barium; or (c) beryllium; or (d) cobalt; or (e) iron oxide; or (f) tin; or (g) tungsten.
35	Byssinosis	Defence service for at least 4 weeks (whether consecutive or not) involving work with: (a) unprocessed cotton; or (b) unprocessed flax; or (c) unprocessed hemp; or (d) unprocessed sisal.
36	Extrinsic allergic alveolitis	Defence service for at least 4 weeks (whether consecutive or not) involving work with: (a) feathers; or (b) grain; or (c) hay; or (d) straw.
Hepatic disease		
37	Non-infectious hepatitis	Defence service involving work with: (a) acrylonitrile; or (b) alcohols; or (c) amino-derivatives of benzene; or (d) antimony; or (e) aromatic hydrocarbons; or (f) arsenic; or (g) benzene; or (h) benzoquinone; or (i) beryllium; or (j) cadmium; or (k) carbon disulphide; or (l) carbon monoxide; or (m) chromium; or (n) copper; or (o) fluorine; or

Authorised Version F2026C00964 registered 02/10/2026

		(p) glycols; or (q) hexane; or (r) hydrogen cyanide; or (s) hydrogen sulphide; or (t) ketones; or (u) lead; or (v) manganese; or (w) mercury; or (x) methylene chloride; or (y) mineral acids; or (z) nitric acid esters; or (za) organochlorine compounds; or (zb) organophosphate; or (zc) osmium; or (zd) oxides of nitrogen; or (ze) ozone; or (zf) phosgene; or (zg) phosphorus; or (zh) selenium; or (zi) styrene; or (zj) thallium; or (zk) tin; or (zl) toluene; or (zm) toxic halogen derivatives of aliphatic; or (zn) toxic nitro-derivatives of benzene; or (zo) vanadium; or (zp) zinc.
Skin diseases		
38	Irritant contact dermatitis	Defence service for at least 4 weeks (whether consecutive or not) involving work and contact with: (a) alcohols; or (b) cutting fluids; or (c) cleaners; or (d) degreasers; or (e) disinfectants; or (f) liquids (frequent contact); or (g) liquids (prolonged contact); or (h) petroleum products; or (i) soaps; or (j) solvents.

Authorised Version F2026C00964 registered 02/10/2026

39	Allergic contact dermatitis	Defence service for at least 4 weeks (whether consecutive or not) involving work and contact with: (a) 2,5-diaminotoluene sulfate; or (b) 4-phenylenediamine base; or (c) ammonium persulfate; or (d) cobalt chloride; or (e) cocamide diethanolamide; or (f) coconut diethanolamide; or (g) colophonium/colophony/rosin; or (h) diazolidinyl urea; or (i) epoxy resin; or (j) formaldehyde; or (k) fragrance mix I: (i) amylcinnamaldehyde; or (ii) cinnamic alcohol; or (iii) cinnamic aldehyde; (iv) eugenol; or (v) geraniol; or (vi) hydroxycitronellal; or (vii) isoeugenol; or (viii) oakmoss absolute; or (l) fragrance mix II: (i) citral; or (ii) citronellol; or (iii) coumarin; or (iv) farnesol; or (v) hexyl cinnamic aldehyde; or (vi) hydroxyisohexyl 3-cyclohexene carboxaldehyde; or (m) glyceryl monothioglycolate; or (n) hydroxyethyl methacrylate; or (o) mercaptobenzothiazole; or (p) methyl chloroisothiazolinone; or (q) mixture of methylchloroisothiazolinone and methylisothiazolinone; or (r) nickel sulfate; or (s) potassium dichromate; or (t) quaternium 15; or (u) thiuram mix: (i) tetramethylthiuramdisulfide; or (ii) tetramethylthiuram monosulfide; or

Authorised Version F2026C00964 registered 02/10/2026

		(iii) tetraethylthiuram disulfide.
40	Occupational vitiligo	Defence service for at least 4 weeks (whether consecutive or not) involving work with: (a) hydroquinone; or (b) monobenzyl ether of hydroquinone; or (c) monobutyl ether of hydroquinone; or (d) para-amylphenol; or (e) para-tertiary-butylcatechol; or (f) para-tertiary-butylphenol.
Musculoskeletal diseases		
41	Raynaud's disease	Defence service for at least 12 weeks (whether consecutive or not) involving work with: (a) powered equipment that produces vibration; or (b) powered tools that produce vibration.
42	Bursitis at the elbow or knee	Defence service for at least 6 months (whether consecutive or not) involving a work activity that: (a) for bursitis at the elbow: (i) involves prolonged external friction at or about the elbow; or (ii) involves prolonged external pressure at or about the elbow; or (iii) involves recurrent external friction at or about the elbow; or (iv) involves recurrent external pressure at or about the elbow; or (b) for bursitis at the knee: (i) involves prolonged external friction at or about the knee; or (ii) involves prolonged external pressure at or about the knee; or (iii) involves recurrent external friction at or about the knee; or (iv) involves recurrent external friction at or about the knee.
Acute diseases		
43	Acute poisoning or toxicity affecting the heart, lungs, liver, kidney, nervous system or blood	The same as for item 37.

Authorised Version F2026C00964 registered 02/10/2026

Part 9—Occupational asthma attributable to specified defence service

15 Attributable disease—occupational asthma

The disease of occupational asthma is attributable to defence service for at least 4 weeks (whether consecutive or not) involving work with an agent or thing specified in column 2 of an item in the table.

	Column 1	Column 2
Item	**Class of agent or thing**	**Specified agent or thing**
1	Arthropods	(a) acarian; or (b) barn mite; or (c) caddisfly; or (d) cricket; or (e) *Ephestia kuehniella* (Mediterranean flour moth); or (f) fowl mite; or (g) fruit fly; or (h) grain mite; or (i) flour mite; or (j) lesser mealworm; or (k) locust; or (l) sheep blowfly; or (m) silkworm.
2	Acids	(a) dodecanedioic acid; or (b) glacial acetic acid; or (c) hydrochloric acid; or (d) peroxyacetic acid; or (e) sulphuric acid; or (f) sulphur dioxide.
3	Acrylates	(a) acrylic acid; or (b) cyanoacrylates; or (c) methyl methacrylate; or (d) polymethyl methacrylate; or (e) trimethylolpropane triacrylate/2-hydroxypropyl acrylate.
4	Aldehydes	(a) formaldehyde; or (b) gluteraldehyde; or (c) paraformaldehyde; or

Authorised Version F2026C00964 registered 02/10/2026

Section 15

		(d) urea formaldehyde.
5	Amines	(a) aminoethyl ethanolamine; or (b) diethanolamine; or (c) dimethylethanolamine; or (d) ethanolamines; or (e) ethylenediamine; or (f) monoethanolamine; or (g) surfactant-specific amines; or (h) triethanolamine; or (i) triethylenetetramine; or (j) trimethylhexane-1; or (k) 6-diamine/isophorondiamine mixture.
6	Ammonias	(a) anhydrous ammonia; or (b) ammonium hydroxide; or (c) ammonia solution 10%; or (d) ammonia solution 29%.
7	Anhydrides	(a) hexahydrophthalic anhydride; or (b) himic anhydride; or (c) maleic anhydride; or (d) methyl tetrahydrophthalic; or (e) anhydride; or (f) phthalic anhydride; or (g) tetrachlorophthalic anhydride; or (h) trimellitic anhydride.
8	Bio-aerosols	(a) *Alternaria*; or (b) *Chrysonilia sitophilia*; or (c) *Neurospora*; or (d) *Penicillium*; or (e) cutting oils.
9	Biological enzymes	(a) *Bacillus subtilis* enzymes; or (b) bromelain; or (c) egg lysozyme; or (d) esperase; or (e) flaviastase; or (f) fungal amylase; or (g) fungal amyloglucosidase; or (h) fungal hemicellulose; or (i) pancreatin; or (j) papain; or (k) pepsin; or

Authorised Version F2026C00964 registered 02/10/2026

		(l) trypsin.
10	Epoxy	(a) epoxy; or (b) epoxy adhesive.
11	Ethylene oxide	ethylene oxide.
12	Flours	(a) buckwheat flour; or (b) rye flour; or (c) soya flour; or (d) wheat flour.
13	Flowers	(a) baby's breath; or (b) freesia; or (c) *Limonium tataricum*; or (d) sunflower.
14	Foods	(a) Brazil ginseng; or (b) castor bean; or (c) chamomile; or (d) cinnamon; or (e) *Dioscorea batatas* (Chinese yam); or (f) egg protein; or (g) fenugreek; or (h) garlic dust; or (i) green beans; or (j) guar; or (k) hops; or (l) paprika; or (m) pectin; or (n) rose hips; or (o) soybean lecithin; or (p) tea; or (q) thiamine (vitamin B); or (r) thyme.
15	Industrial cleaning and sterilising agents	(a) alkyl dimethyl benzyl ammonium chloride; or (b) benzyl-C10-16-alkyldimethyl, chlorides; or (c) benzyl-C12-16-alkyldimethyl, chlorides; or (d) benzyl-C12-18-alkyldimethyl, chlorides; or (e) benzyl-C16-18-alkyldimethyl, chlorides; or (f) benzyldimethylstearyl ammonium chloride; or (g) cetalkonium chloride; or (h) chlorhexidine; or (i) chlorine; or (j) dialkyl methyl benzyl ammonium chloride; or

Authorised Version F2026C00964 registered 02/10/2026

Section 15

		(k) dicumyl-peroxide; or (l) dodecyl dimethyl ammonium chloride; or (m) dimethyl ethyl benzyl ammonium chloride; or (n) dodecyl-dimethylbenzylammonium; or (o) fluorine; or (p) n-alkyl dimethyl benzyl ammonium chloride; or (q) persulphate salts; or (r) sodium hypochlorite; or (s) sodium metabisulfite.
16	Isocyanates	(a) diisocyanates; or (b) hexamethylene diisocyanate prepolymers; or (c) isocyanates; or (d) toluene diisocyanate prepolymers.
17	Latex	(a) latex; or (b) natural rubber.
18	Medications	(a) ampicillin; or (b) amprolium; or (c) cimetidine; or (d) codeine; or (e) colistin; or (f) hydralazine; or (g) ipecacuanha; or (h) hydrocodone; or (i) isonicotinic acid hydrazide; or (j) methyldopa; or (k) morphine; or (l) opiate compounds; or (m) oxycodone; or (n) papaverine; or (o) penicillamine; or (p) penicillins; or (q) phenylglycine acid chloride; or (r) psyllium; or (s) salbutamol intermediate; or (t) spiramycin; or (u) tetracycline; or (v) thebaine; or (w) tylosin tartrate; or (x) vancomycin.
19	Metals	(a) aluminium; or

Authorised Version F2026C00964 registered 02/10/2026

		(b) aluminium chloride; or (c) aluminium oxide; or (d) aluminium compounds; or (e) ammonium dichromate; or (f) ammonium hexachloroplatinate (IV); or (g) chromium; or (h) chromium, metal; or (i) chromium, hexavalent; or (j) chromium, non-hexavalent; or (k) cobalt; or (l) cobalt compounds; or (m) nickel; or (n) nickel compounds; or (o) platinum; or (p) rhodium; or (q) soluble halogenated platinum compounds; or (r) titanium oxide/dioxide; or (s) tributyl tin oxide; or (t) tungsten carbide; or (u) tungsten carbide/cobalt; or (v) vanadium; or (w) welding fumes – gas metal arc welding on uncoated mild steel; or (x) welding fumes – stainless steel; or (y) stainless steel; or (z) zinc oxide.
20	Other reactive chemicals	(a) chlorofluorocarbon refrigerants heated; or (b) fluoride; or (c) furfuryl alcohol mixed with a catalyst; or (d) isolyzer; or (e) polyethylene terephthalate/polybutylene terephthal; or (f) polyfunctional aziridine; or (g) polypropylene heated; or (h) polyvinyl chloride heated; or (i) polyvinyl chloride non-heated; or (j) polyvinyl chloride thermally degraded; or (k) radiographic fixative; or (l) resin containing furfuryl alcohol; or (m) styrene; or (n) trigylicidyl isocyanurate.

Authorised Version F2026C00964 registered 02/10/2026

Section 15

21	Pesticides	(a) 3-amino-5-mercapto-1;2;4-triazole; or (b) acephate; or (c) chloramine T; or (d) chlorothalonil (bravo, echo); or (e) diazinon; or (f) dimethoate; or (g) fenthion; or (h) malathion; or (i) nemacur; or (j) piperazine; or (k) piperazine citrate; or (l) piperazine hydrochloride; or (m) pyrethrins; or (n) pyrfon; or (o) safrotin; or (p) tetramethrin.
22	Plants and sensitising agents or irritants derived from plants	(a) almond dust; or (a) *Arabidopsis thaliana*; or (b) *Chlorella* algae; or (c) gum arabic; or (d) henna; or (e) kapok; or (f) linseed oilcake; or (g) *Pinellia ternata*; or (h) quillaja bark; or (i) rice dust; or (j) tall oil crude; or (k) tall oil – rosin; or (l) tobacco leaf; or (m) tragacanth; or (n) turpentine; or (o) *Vicia sativa* (vetch); or (p) weeping fig.
23	Reactive dyes	(a) Cibachrome Brilliant Scarlet 32; or (b) Drimarene Brilliant Blue K-BL; or (c) Drimarene Brilliant Yellow K-3GL; or (d) Lanasol Yellow 4G; or (e) Levafix Brilliant Yellow E36; or (f) Methyl Blue; or (g) Rifacion Orange HE 2G; or

Authorised Version F2026C00964 registered 02/10/2026

		(h) Rifafix Yellow 3 RN; or (i) Rifazol Black GR; or (j) Rifazol Brilliant Orange 3R.
24	Sensitising agents or irritants derived from animals	(a) bat guano; or (b) bovine serum albumin; or (c) casein; or (d) cat antigens; or (e) chicken antigens; or (f) cow antigens; or (g) frog antigens; or (h) guinea pig antigens; or (i) lactoserum; or (j) mice antigens; or (k) pig antigens; or (l) rabbit antigens; or (m) rat antigens.
25	Sensitising agents or irritants derived from fish or shellfish	(a) *Anisakis simplex* (herring worm) antigens; or (b) clam antigens; or (c) crab antigens; or (d) cuttlefish antigens; or (e) fishmeal; or (f) nacre dust; or (g) octopus antigens; or (h) prawn antigens; or (i) red soft coral antigens; or (j) salmon antigens; or (k) shrimp meal; or (l) trout antigens.
26	Soldering fluxes	(a) colophony soldering flux; or (b) alkyl aryl polyether soldering flux; or (c) zinc soldering flux.
27	Wood	(a) *Triplochiton scleroxylon* (African maple); or (b) *Acacia melanoxylon* (blackwood); or (c) *Sequoia sempervirens* (California redwood); or (d) *Juglans olanchana* (Central American walnut); or (e) *Thuja occidentalis* (eastern white cedar); or (f) *Shoreal sp.* (mahogany); or (g) *Quercus robur* (oak); or (h) *Thuja lpicata* (western red cedar).

Authorised Version F2026C00964 registered 02/10/2026

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history

Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes
The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and "(md not incorp)" is added to the amendment history.

Authorised Version F2026C00964 registered 02/10/2026

Endnote 2—Abbreviation key

ad = added or inserted

am = amended

amdt = amendment

C[x] = Compilation No. x

ch = Chapter(s)

cl = clause(s)

cont. = continued

def = definition(s)

Dict = Dictionary

disallowed = disallowed by Parliament

div = Division(s)

ed = editorial change

exp = expires/expired or ceases/ceased to have effect

gaz = gazette

LA = *Legislation Act 2003*

LIA = *Legislative Instruments Act 2003*

(md) = misdescribed amendment can be given effect

(md not incorp) = misdescribed amendment cannot be given effect

mod = modified/modification

No. = Number(s)

Ord = Ordinance

orig = original

p = page(s)

para = paragraph(s)/subparagraph(s) /sub-subparagraph(s)

pres = present

prev = previous

(prev…) = previously

pt = Part(s)

r = regulation(s)/Court rule(s)

reloc = relocated

renum = renumbered

rep = repealed

rs = repealed and substituted

s = section(s)/subsection(s) /rule(s)/subrule(s)/order(s)/suborder(s)

sch = Schedule(s)

SLI = Select Legislative Instrument

SR = Statutory Rules

sub ch = Sub-Chapter(s)

sub div = Subdivision(s)

sub pt = Subpart(s)

underlining = whole or part not commenced or to be commenced

Authorised Version F2026C00964 registered 02/10/2026

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
Military Rehabilitation and Compensation (Injuries and Diseases Attributable to Defence Service—Presumptive Liability) Determination 2026	18 June 2026 (F2026L00740)	1 July 2026 (s 2)	
Military Rehabilitation and Compensation (Injuries and Diseases Attributable to Defence Service—Presumptive Liability) Amendment Determination 2026	25 Sept 2026 (F2026L01302)	26 Sept 2026 (s 2)	—

Authorised Version F2026C00964 registered 02/10/2026

Endnote 4—Amendment history

Provision affected	How affected
Part 1	
s 2.....	rep LA s 48D
Part 4	
s 9.....	am F2026L01302

Authorised Version F2026C00964 registered 02/10/2026